Insurance; health benefit policy coverage for biomarker testing if supported by medical and scientific evidence; require
Impact
The legislation intends to enhance access to innovative diagnostic methods that leverage biomarker testing, which can guide treatment options for a variety of diseases, including cancer. By standardizing coverage requirements, the bill seeks to limit disruptions in patient care, like unnecessary biopsies or testing delays. Importantly, it proposes that health insurance entities must respond to prior authorization requests for biomarker tests within predetermined timeframes, thereby streamlining the process for healthcare providers and patients alike.
Summary
House Bill 659 aims to mandate coverage for biomarker testing under health benefit policies in Georgia, contingent upon affirmation by medical and scientific evidence. The bill specifically amends existing health insurance laws by defining key terms related to biomarker testing and outlining the conditions under which such testing should be covered. With this legislation, all health benefit policies renewed or issued after July 1, 2023, would be required to include this coverage, thus ensuring that patients are not denied this important medical technology for diagnosis and treatment based on arbitrary exclusions.
Contention
However, potential points of contention include concerns from insurance companies about the financial implications of mandated coverage. Critics may argue that imposing such requirements might increase premiums or limit the risks for insurers. Balancing the need for comprehensive healthcare access and the financial sustainability of insurance programs will likely be a central debate surrounding HB 659. Additionally, there could be discussions on how diagnostics evolve swiftly, and whether statute can keep pace with the pace of scientific advancement.